---
title: "PRDM16"
date: 2023-05-15 00:00:00
layout: post
categories: Gene
summary: "# Gene: PRDM16"
tags: ['PRDM16', 'TranscriptionFactor', 'AdiposeTissue', 'Thermogenesis', 'Leukemia', 'BreastCancer', 'PolycythemiaVera', 'DrugTargeting']
---

# Gene: PRDM16

## Information

### Gene Position, Pathology, and Function

- **Gene Position**: Chromosome 1 (1p36.32)
- **Pathology**: PRDM16 has been associated with various diseases, including acute myeloid leukemia, breast cancer, and polycythemia vera
- **Function**: PRDM16 is a transcription factor that plays a crucial role in adipose tissue development and brown fat thermogenesis. It also plays a role in hematopoietic differentiation.

## External IDs and Aliases

- **Gene ID**: 63976
- **Genomic Location**: NC_000001.11 (1243944..1342097)
- **Aliases**: MEL1, AT591, KMT8F, ZNF422

### External Sites

- **HGNC**: HGNC:23092
- **NCBI Entrez**: 63976
- **Ensembl**: ENSG00000167874
- **OMIM**: 605557
- **UniProtKB/Swiss-Prot**: Q9HAZ2

## AA Mutation List and Mutation Type with dbSNP ID

- c.88G>A, p.Gly30Asp, rs143314287
- c.311C>T, p.Arg104Trp, rs201766780
- c.439C>A, p.Pro147Thr, rs372985759
- c.1055C>T, p.Thr352Met, rs796954393

## Somatic SNVs/InDels with dbSNP ID

- c.313A>G, rs148210361
- c.341G>A, rs139250954
- c.520A>G, rs368873019
- c.733G>T, rs794726057

## Related Disease

- Acute myeloid leukemia
- Breast cancer
- Polycythemia vera

## Treatment and Prognosis

Current treatments for PRDM16-associated diseases vary depending on the specific condition. For example, in acute myeloid leukemia, patients may receive chemotherapy or a bone marrow transplant. In breast cancer, treatment may involve surgery, radiation therapy, or chemotherapy. Polycythemia vera is often treated with phlebotomy, medications that reduce the production of red blood cells, or blood thinners.

Prognosis also varies depending on the disease. Acute myeloid leukemia has a relatively poor prognosis, with a five-year survival rate of around 25%. Breast cancer survival rates vary widely depending on the stage of the cancer at diagnosis, ranging from nearly 100% for early-stage cancer to around 27% for stage IV cancer. Polycythemia vera is generally considered a chronic condition, and with proper treatment, many patients can live a relatively normal life.

## Drug Response

There is currently limited information on drug response for PRDM16-associated diseases. However, some studies have suggested that targeting PRDM16 could be a potential therapeutic strategy for certain cancers.

## Related Papers

- *PRDM16 as a Smad/C-Myc Combinatorial Molecule and Critical Oncogenic Focal Point in Prostate Cancer Development*, DOI: 10.1186/s12885-020-07572-5
- *PRDM16 knockout inhibits the proliferation of breast cancer cell by inducing cell cycle arrest and promoting apoptosis*, DOI: 10.1371/journal.pone.0230686
- *Development of a high-throughput screen to identify inhibitors of PRDM16 bromodomain*, DOI: 10.1186/s13036-020-00250-z

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**